Baldanti F, Silini E, Sarasini A, Talarico C L, Stanat S C, Biron K K, Furione M, Bono F, Palù G, Gerna G
Virus Laboratory, University of Pavia, IRCCS Policlinico S. Matteo, Italy.
J Virol. 1995 Feb;69(2):796-800. doi: 10.1128/JVI.69.2.796-800.1995.
Multiple human cytomegalovirus (HCMV) strains frequently coexist in patients with AIDS, and chronic ganciclovir treatment may favor the emergence of ganciclovir-resistant viral mutants. We report the molecular and biochemical characterization of a HCMV ganciclovir-resistant strain (VR3480) previously recovered from a patient with AIDS who was undergoing multiple courses of ganciclovir treatment (G. Gerna, F. Baldanti, M. Zavattoni, A. Sarasini, E. Percivalle, and M. G. Revello, Antiviral Res. 19:333-345, 1992). Ganciclovir resistance of strain VR3480 was related to impaired ability to monophosphorylate the drug, as indicated by the finding that ganciclovir phosphorylation values for VR3480 were 30% of those shown by the HCMV reference strain AD169 in an in vitro activity assay. Sequencing of the UL97 gene of VR3480, which encodes the viral kinase responsible for ganciclovir phosphorylation, showed an in-frame deletion of three nucleotides resulting in the loss of a leucine at position 595 in the polypeptide. Mutant VR3480 UL97 DNA was able to transfer resistance to the AD169 strain in marker rescue experiments. Analysis of virus isolates and blood polymorphonuclear leukocyte samples spanning the 2-year follow-up period of the patient showed that ganciclovir-resistant strain VR3480 arose ex novo during prolonged antiviral treatment and accounted for the majority of virus load circulating in blood during the period of clinical resistance to ganciclovir treatment.
多种人类巨细胞病毒(HCMV)毒株经常共存于艾滋病患者体内,长期使用更昔洛韦治疗可能会促使产生更昔洛韦耐药的病毒突变体。我们报告了一株HCMV更昔洛韦耐药毒株(VR3480)的分子和生化特征,该毒株先前从一名正在接受多个疗程更昔洛韦治疗的艾滋病患者体内分离得到(G. 杰尔纳、F. 巴尔丹蒂、M. 扎瓦托尼、A. 萨拉西尼、E. 佩尔西瓦莱和M. G. 雷韦洛,《抗病毒研究》19:333 - 345,1992年)。VR3480毒株对更昔洛韦的耐药性与该药物单磷酸化能力受损有关,体外活性试验结果表明,VR3480的更昔洛韦磷酸化值仅为HCMV参考毒株AD169的30%。对VR3480的UL97基因进行测序,该基因编码负责更昔洛韦磷酸化的病毒激酶,结果显示有三个核苷酸的框内缺失,导致多肽第595位的亮氨酸缺失。在标记拯救实验中,突变体VR3480的UL97 DNA能够将耐药性转移至AD169毒株。对该患者长达2年随访期内的病毒分离株和血液多形核白细胞样本进行分析,结果表明,更昔洛韦耐药毒株VR3480是在长期抗病毒治疗过程中重新出现的,并且在对更昔洛韦治疗产生临床耐药的期间,它在血液中循环的病毒载量中占大多数。